These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18552880)

  • 21. Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia.
    Löscher W; Richter A
    Eur J Pharmacol; 2000 Mar; 391(3):251-4. PubMed ID: 10729365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam.
    Kaminski RM; Matagne A; Patsalos PN; Klitgaard H
    Epilepsia; 2009 Mar; 50(3):387-97. PubMed ID: 18627416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levetiracetam monotherapy--outcomes from an epilepsy clinic.
    Stephen LJ; Kelly K; Parker P; Brodie MJ
    Seizure; 2011 Sep; 20(7):554-7. PubMed ID: 21531583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inter-individual variation in the effect of antiepileptic drugs in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice.
    Klein S; Bankstahl M; Löscher W
    Neuropharmacology; 2015 Mar; 90():53-62. PubMed ID: 25460186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus.
    Tai KK; Truong DD
    J Neural Transm (Vienna); 2007; 114(12):1547-51. PubMed ID: 17690949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brivaracetam augments short-term depression and slows vesicle recycling.
    Yang X; Bognar J; He T; Mohammed M; Niespodziany I; Wolff C; Esguerra M; Rothman SM; Dubinsky JM
    Epilepsia; 2015 Dec; 56(12):1899-909. PubMed ID: 26515103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiepileptic drug discovery: lessons from the past and future challenges.
    Klitgaard H
    Acta Neurol Scand Suppl; 2005; 181():68-72. PubMed ID: 16238713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis.
    Luszczki JJ; Andres MM; Czuczwar P; Cioczek-Czuczwar A; Ratnaraj N; Patsalos PN; Czuczwar SJ
    Epilepsia; 2006 Jan; 47(1):10-20. PubMed ID: 16417526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs.
    Ji-qun C; Ishihara K; Nagayama T; Serikawa T; Sasa M
    Epilepsia; 2005 Sep; 46(9):1362-70. PubMed ID: 16146430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator.
    Stahl SM
    J Clin Psychiatry; 2004 Sep; 65(9):1162-3. PubMed ID: 15367040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antiepileptic drugs in North America].
    Akiyama T; Otsubo H
    Brain Nerve; 2010 May; 62(5):519-26. PubMed ID: 20450099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?
    Swallow E; Fang A; Signorovitch J; Plumb J; Borghs S
    CNS Drugs; 2017 Oct; 31(10):899-910. PubMed ID: 28856580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levetiracetam: a comprehensive review.
    Crepeau AZ; Treiman DM
    Expert Rev Neurother; 2010 Feb; 10(2):159-71. PubMed ID: 20136375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacology and clinical results of levetiracetam (E Keppra(®) Tablets), a new antiepileptic drug].
    Ishii Y; Tanaka T
    Nihon Yakurigaku Zasshi; 2011 Feb; 137(2):95-102. PubMed ID: 21321459
    [No Abstract]   [Full Text] [Related]  

  • 36. Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam.
    Klitgaard H; Pitkänen A
    Epileptic Disord; 2003 May; 5 Suppl 1():S9-16. PubMed ID: 12915336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levetiracetam add-on for drug-resistant localization related (partial) epilepsy.
    Chaisewikul R; Privitera MD; Hutton JL; Marson AG
    Cochrane Database Syst Rev; 2001; (1):CD001901. PubMed ID: 11279737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles.
    Genton P; Van Vleymen B
    Epileptic Disord; 2000 Jun; 2(2):99-105. PubMed ID: 10954241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Levetiracetam in the treatment of epilepsy].
    Mariero Klees T; Brodtkorb E; Nakken KO; Lossius R; Johannessen SI
    Tidsskr Nor Laegeforen; 2003 May; 123(11):1539-41. PubMed ID: 12822020
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.